These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 30780853)

  • 21. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
    Hall MJ; Adin CA; Borin-Crivellenti S; Rudinsky AJ; Rajala-Schultz P; Lakritz J; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():114-21. PubMed ID: 25625650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date.
    Howell R; Wright AM; Clements JN
    Diabetes Metab Syndr Obes; 2019; 12():505-512. PubMed ID: 31118715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of incretin mimetics on cardiovascular risk factors in diabetes.
    Kinalska I; Bednarska-Chabowska D; Adamiec-Mroczek J; Hak L
    ISRN Endocrinol; 2012; 2012():625809. PubMed ID: 22462016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide Overdose-Induced Acute Pancreatitis.
    AlSaadoun AR; AlSaadoun TR; Al Ghumlas AK
    Cureus; 2022 Jan; 14(1):e21616. PubMed ID: 35228970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erratum to: Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
    DellaValle B; Hempel C; Staalsoe T; Johansen FF; Kurtzhals JAL
    Malar J; 2016; 15():495. PubMed ID: 31265540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.
    Masood A; Benabdelkamel H; Joy SS; Alhossan A; Alsuwayni B; Abdeen G; Aldhwayan M; Alfadda NA; Miras AD; Alfadda AA
    Front Mol Biosci; 2024; 11():1458675. PubMed ID: 39324112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.
    Shao Y; Chen Y; Zhu M; Liu Y; Fang C; Wang M; Sun P; Fu W; Huang J; Sheng S; Huang Y
    Diabetes Metab Syndr Obes; 2024; 17():1563-1573. PubMed ID: 38601038
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.